Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...

David Lebowitz, an analyst from Citi, maintained the Buy rating on BridgeBio Pharma (BBIO – Research Report). The associated price target is ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

But the good news is, getting tested is usually quick, easy, and painless. And STDs can be cured or treated. Planned Parenthood health centers offer STD testing and treatment, and our caring and ...

Neuralgia, characterized by acute paroxysmal pain radiating along the course of one or more nerves, is a significant concern ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Johnson & Johnson announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society of ...